- Home
- LKFN vs CGON Comparison
LKFN vs CGON Comparison
Compare LKFN & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LKFN
- CGON
- Stock Information
- Founded
- LKFN 1872
- CGON 2010
- Country
- LKFN United States
- CGON United States
- Employees
- LKFN N/A
- CGON N/A
- Industry
- LKFN Major Banks
- CGON
- Sector
- LKFN Finance
- CGON
- Exchange
- LKFN Nasdaq
- CGON NYSE
- Market Cap
- LKFN 1.3B
- CGON 1.3B
- IPO Year
- LKFN 1997
- CGON 2024
- Fundamental
- Price
- LKFN $60.90
- CGON $24.17
- Analyst Decision
- LKFN Buy
- CGON Strong Buy
- Analyst Count
- LKFN 2
- CGON 11
- Target Price
- LKFN $65.00
- CGON $62.90
- AVG Volume (30 Days)
- LKFN 234.3K
- CGON 2.0M
- Earning Date
- LKFN 04-25-2025
- CGON 05-13-2025
- Dividend Yield
- LKFN 3.27%
- CGON N/A
- EPS Growth
- LKFN N/A
- CGON N/A
- EPS
- LKFN 3.50
- CGON N/A
- Revenue
- LKFN $236,268,000.00
- CGON $662,000.00
- Revenue This Year
- LKFN $16.03
- CGON N/A
- Revenue Next Year
- LKFN $4.31
- CGON $13,724.75
- P/E Ratio
- LKFN $17.56
- CGON N/A
- Revenue Growth
- LKFN N/A
- CGON 224.51
- 52 Week Low
- LKFN $50.00
- CGON $14.80
- 52 Week High
- LKFN $78.61
- CGON $40.47
- Technical
- Relative Strength Index (RSI)
- LKFN 63.29
- CGON 50.83
- Support Level
- LKFN $59.02
- CGON $21.00
- Resistance Level
- LKFN $62.34
- CGON $25.81
- Average True Range (ATR)
- LKFN 1.69
- CGON 2.34
- MACD
- LKFN 0.78
- CGON -0.03
- Stochastic Oscillator
- LKFN 88.33
- CGON 28.05
About LKFN Lakeland Financial Corporation
Lakeland Financial Corp is a bank holding company. It provides commercial, retail, wealth advisory, and investment management services. Lakeland offers a broad range of products and services throughout its Northern and Central Indiana markets. The company offers commercial and consumer banking services, as well as trust and wealth management, brokerage, and treasury management commercial services. It serves a wide variety of industries including, among others, commercial real estate, manufacturing, agriculture, construction, retail, wholesale, finance and insurance, accommodation and food services, and healthcare.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.